Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes

Diabetes Care

Volumn 39, Issue 4, 2016, Pages 532-538

  Peters, Anne L ^a   Henry, Robert R ^b,c   Thakkar, Payal ^d   Tong, Cindy ^d   Alba, Maria ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE; PLACEBO; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DIABETIC KETOACIDOTIC HYPERGLYCEMIC COMA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KETONURIA; MALE; MEDICATION COMPLIANCE; METABOLIC ACIDOSIS; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ANTAGONISTS AND INHIBITORS; BODY MASS; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; INSULIN INFUSION;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84962053997     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1995     Document Type: Article

References (24)

1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-1343
2. Trachtenbarg DE. Diabetic ketoacidosis. Am Fam Physician 2005;71:1705-1714
3. Perilli G, Saraceni C, Daniels MN, Ahmad A. Diabetic ketoacidosis: a review and update. Curr Emerg Hosp Med Rep 2013;1:10-17
4. Leslie RD, Kolb H, Schloot NC, et al. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev 2008;24: 511-519
5. Laugesen E, Østergaard JA, Leslie RD; Danish Diabetes Academy Workshop and Workshop Speakers. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Dia-bet Med 2015;32:843-852
6. Umpierrez GE, Murphy MB, Kitabchi AE. Diabetic ketoacidosis and hyperglycemic hyperos-molar syndrome. Diabetes Spectr 2002;15: 28-36
7. Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [article online], 2015. Available from http://www.fda .gov/Drugs/DrugSafety/ucm446845.htm. Accessed 19 May 2015
8. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started. Risk of diabetic ketoacidosis to be examined [article online], 2015. Available from http://www.ema .europa.eu/ema/index.jsp?curl=pages/medicines/ human/referrals/SGLT2-inhibitors/human-referral- prac-000052.jsp&mid=WC0b01ac05805c516f. Accessed 25 June 2015
9. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-545
10. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-672
11. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:E867-E871
12. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-419
13. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-1483
14. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38:1181-1188
15. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes mellitus. Diabetes Care 2015;38:2258-2265
16. Argento NB, Nakamura K. Glycemic effects of SGLT-2 inhibitor canagliflozin in type 1 diabetes using Dexcom G4 Platinum CGM. Endocr Pract. 2 November 2015 [Epub ahead of print]. DOI: 10.4158/EP151016.OR
17. Pieber TR, Famulla S, Eilbracht J, et al. Em-pagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015;17:928-935
18. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoaci-dosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-1693
19. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-1642
20. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin En-docrinol Metab 2015;100:2849-2852
21. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotrans-porter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508
22. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512-517
23. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012;97:4383-4389
24. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015;38:1680-1686